The United States is currently in a race against the clock, as states try to vaccinate as many Americans as possible before new variants begin to dominate the country. Now, a very exciting new development this weekend is about to make this mission a little easier: a third Johnson & Johnson COVID-19 vaccine has been approved for emergency use in the United States. In addition to being 100 percent effective against hospitalizations and deaths, it is also administered in a single injection, potentially doubling our progress in getting the coveted 70% to 85% of the population to be vaccinated in order to achieve collective immunity. So, when will this new photo be available? Sooner than you think, experts say. Read on to find out when the Johnson & Johnson vaccine may be in a location near you and for more information on the latest vaccine guidelines, consult Dr. Fauci Just Said, do not take this medicine with the COVID vaccine.
The first deliveries of the Johnson & Johnson vaccine may arrive on Tuesday, after a US Center for Disease Control and Prevention (CDC) advisory panel passed a unanimous vote on Sunday to recommend the vaccine for widespread use to Americans with over 18 years.
During a Monday interview with Today, CEO of Johnson & Johnson Alex Gorsky said: “In the next 24 to 28 hours, Americans should start receiving gunfire. They are literally being launched with the trucks as we speak. ”And for more vaccine news you need to know, check out The Pfizer vaccine may be less effective if you have this common condition.
The original delivery is set for 4 million doses. Johnson & Johnson plans to ship more than 20 million doses of the vaccine by the end of March and 100 million doses by June, which is what the United States was promised, said Gorsky during his Today interview that Johnson & Johnson expects to be “up to one billion by the end of 2021”, adding, “We will work hard to ensure that all of these commitments are met.” And for more regular COVID updates sent straight to your inbox, sign up for our daily newsletter.
In addition to requiring only one injection instead of two, the Johnson & Johnson vaccine differs from Pfizer and Moderna vaccines in that it does not require freezing to maintain its effectiveness, which should facilitate its transportation across the country. While federal authorities have emphasized that all three vaccines must be uniformly available across the country, the dispensation of special storage and transportation facilities will make Johnson & Johnson vials easier to deliver to hard-to-reach areas and communities.
The authorities are aware that vaccination rates are currently decreasing in minority communities, in particular for a number of reasons. A senior White House official quoted by Reuters said recently, “While we know the data is not complete, we see these initial patterns that suggest that black and brown Americans are being vaccinated at rates lower than representation in the general population.”
One attempt to address this is to open up to 400 community vaccination centers in areas with large minority populations, along with mobile vaccination units. Without the need for freezing or a follow-up visit for a booster injection, the hope is that this new vaccine from Johnson & Johnson will help close that gap quickly and protect more Americans as quickly as possible. And for more news on this new vaccine, check out The Johnson & Johnson Vaccine is 100% Effective This One Thing.
There has been some discussion that Johnson & Johnson is the “weakest” vaccine, as its rate of effectiveness against symptomatic COVID in the US is 72% against Moderna and about 95% protection from Pfizer. But Gorsky explained how those numbers don’t tell the full story. “What is really important to remember about this vaccine is that when we conducted our clinical trials in October 2020 to around January 2021, it was during the period when the virus incident rate was really almost at its peak,” he said. he about Today.
Gorsky said that clinical trials for the Johnson & Johnson vaccine have been conducted worldwide, with 40% of patients in Latin America and 15% in South Africa, where the Brazilian and South African variants, respectively, are becoming increasingly common. increasingly dominant. “When you look at the numbers around the vaccine, what is most important is that it works 85 percent of the time against serious illnesses and has prevented all patients from dying and hospitalizing, even against these new and really challenging variants,” he said. Gorsky. Meanwhile, Moderna and Pfizer vaccines have not been tested against variants until more recently, which is why these pharmaceutical companies are working on booster vaccines to protect themselves against variants now. And for more information on the future of COVID vaccines, see The CEO of Pfizer says the need for a COVID vaccine is frequent.